[ 44 ] The degree of morbidity of irAEs can be quite significant, requiring changing or discontinuation of ICI therapy, there exists a need to select a target to prevent or treat irAEs in this vulnerable patient population.
← all excerpts
Cytokines in PD-1 immune checkpoint inhibitor adverse events and implications for the treatment of uveitis.
1
—
—